(Reuters) – Sales of Bristol-Myers Squibb Co’s cancer drug Abraxane have been suspended in China based on findings at a third-party manufacturing plant in the United States.
The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday.
Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers’ Celgene unit in 2017 to market and distribute Abraxane.
“This decision only applies to the China market and does not impact our ability to supply Abraxane outside of China,” Bristol-Myers said in an emailed statement.
The drug brought in sales of $1.2 billion for Bristol-Myers in 2019.
Along with remediation efforts at the U.S. site, Bristol-Myers has applied for approval to source its supply of Abraxane for the China market from an alternative manufacturing facility, Beigene said.
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli and Vinay Dwivedi